Global Famotidine Market

Famotidine Comprehensive Study by Type (Solution, Tablet), Application (Medical, Microbiology, Others), Route of Administration (Oral, Injection), Treatment (Zollinger-Ellison Syndrome, Gastroesophageal Reflux Disorder (GERD), Erosive Esophagitis, Other), Dosage (0-10 mg, Between 10-20 mg, Above 20mg), End User (Adult, Children) Players and Region - Global Market Outlook to 2030

Famotidine Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 5.3%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
Global Famotidine Market Overview:
Famotidine is a white to pale yellow crystalline compound that is freely soluble in glacial acetic acid, slightly soluble in methanol, very slightly soluble in water, and practically insoluble in ethanol. It is a prescription and over the counter drug used to treat ulcers of the stomach and intestines and to prevent intestinal ulcers from coming back after they have healed. Famotidine is also used to treat certain stomach and throat problems such as erosive esophagitis, gastroesophageal reflux disease, and Zollinger-Ellison syndrome. It is sold under different brand names such as Pepcid, Act, Dyspep HB, Fluxid, and Acid Controller. As per latest study released by AMA Research, the Global Famotidine market is expected to see growth rate of 5.3%

AttributesDetails
Study Period2018-2030
Base Year2023
Forecast Period2024-2030
Historical Period2018-2023
UnitValue (USD Million)
Customization ScopeAvail customization with purchase of this report. Add or modify country, region & or narrow down segments in the final scope subject to feasibility


Influencing Trend:
Treatment for Esophagitis

Market Growth Drivers:
Increasing Use of Famotidine to Treat Acid Indigestion, Growing Demand for Famotidine Tablet and Increasing Use to Treat Zollinger-Ellison Syndrome

Challenges:
Availability of Alternative Treatments

Restraints:
Famotidine May Cause Some Unwanted Side Effects

Opportunities:
Growing Occurrence of Stomach and Intestine Problems among People and Increasing Use of Famotidine in Children

Competitive Landscape:
The key manufacturers are targeting the innovations of the products with better quality, better technical characteristics, and also assist in providing and humanizing the after-sale service to the consumers. The key players are probable to keep a stronghold on the market over the anticipated period. The key players are accepting strategic decisions and are thinking upon mergers and acquisitions in order to maintain their presence in the market
Some of the key players profiled in the report are Uquifa (Spain), Rakshit Drugs Private Limited (India), Chempro Pharma (India), Gauri Fine Chemicals (India), Darou Pakhsh Pharma Chem Co. (Iran), Pat Impex (India), Wuhan Jayusion Pharmaceutical Technology Co., Ltd (China), Phalanx Labs (India), Teva Pharmaceuticals (United States), Aurobindo Pharma (United States), Alembic Pharmaceuticals Inc (United States), Mylan Laboratories Ltd. (United States), Ercros (Spain) and Jeil Pharmaceutical (South Korea). Analyst at AMA Research see Global Players to retain maximum share of Global Famotidine market by 2030. Considering Market by Route of Administration, the sub-segment i.e. Oral will boost the Famotidine market. Considering Market by Treatment, the sub-segment i.e. Zollinger-Ellison Syndrome will boost the Famotidine market. Considering Market by Dosage, the sub-segment i.e. 0-10 mg will boost the Famotidine market. Considering Market by End User, the sub-segment i.e. Adult will boost the Famotidine market.

Latest Market Insights:
In June 2023, Teva Pharmaceuticals introduced Famotidine IV in the US. This injectable form of Famotidine offers a new option for patients unable to take oral medication.

In November 2023, Perrigo launched generic Famotidine chewable tablets in the US. This expands the availability of Famotidine in a convenient dosage form for adults and children.

What Can be Explored with the Famotidine Market Study
 Gain Market Understanding
 Identify Growth Opportunities
 Analyze and Measure the Global Famotidine Market by Identifying Investment across various Industry Verticals
 Understand the Trends that will drive Future Changes in Famotidine
 Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals

Research Methodology:
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Famotidine market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Famotidine market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes New Entrants/Investors, Analysts and Strategic Business Planners, Famotidine Manufacturer, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms, Government Regulatory and Research Organizations and End Use Industry.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.

Report Objectives / Segmentation Covered

By Type
  • Solution
  • Tablet
By Application
  • Medical
  • Microbiology
  • Others
By Route of Administration
  • Oral
  • Injection

By Treatment
  • Zollinger-Ellison Syndrome
  • Gastroesophageal Reflux Disorder (GERD)
  • Erosive Esophagitis
  • Other

By Dosage
  • 0-10 mg
  • Between 10-20 mg
  • Above 20mg

By End User
  • Adult
  • Children

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Use of Famotidine to Treat Acid Indigestion
      • 3.2.2. Growing Demand for Famotidine Tablet
      • 3.2.3. Increasing Use to Treat Zollinger-Ellison Syndrome
    • 3.3. Market Challenges
      • 3.3.1. Availability of Alternative Treatments
    • 3.4. Market Trends
      • 3.4.1. Treatment for Esophagitis
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Famotidine, by Type, Application, Route of Administration, Treatment, Dosage, End User and Region (value, volume and price ) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Famotidine (Value)
      • 5.2.1. Global Famotidine by: Type (Value)
        • 5.2.1.1. Solution
        • 5.2.1.2. Tablet
      • 5.2.2. Global Famotidine by: Application (Value)
        • 5.2.2.1. Medical
        • 5.2.2.2. Microbiology
        • 5.2.2.3. Others
      • 5.2.3. Global Famotidine by: Route of Administration (Value)
        • 5.2.3.1. Oral
        • 5.2.3.2. Injection
      • 5.2.4. Global Famotidine by: Treatment (Value)
        • 5.2.4.1. Zollinger-Ellison Syndrome
        • 5.2.4.2. Gastroesophageal Reflux Disorder (GERD)
        • 5.2.4.3. Erosive Esophagitis
        • 5.2.4.4. Other
      • 5.2.5. Global Famotidine by: Dosage (Value)
        • 5.2.5.1. 0-10 mg
        • 5.2.5.2. Between 10-20 mg
        • 5.2.5.3. Above 20mg
      • 5.2.6. Global Famotidine by: End User (Value)
        • 5.2.6.1. Adult
        • 5.2.6.2. Children
      • 5.2.7. Global Famotidine Region
        • 5.2.7.1. South America
          • 5.2.7.1.1. Brazil
          • 5.2.7.1.2. Argentina
          • 5.2.7.1.3. Rest of South America
        • 5.2.7.2. Asia Pacific
          • 5.2.7.2.1. China
          • 5.2.7.2.2. Japan
          • 5.2.7.2.3. India
          • 5.2.7.2.4. South Korea
          • 5.2.7.2.5. Taiwan
          • 5.2.7.2.6. Australia
          • 5.2.7.2.7. Rest of Asia-Pacific
        • 5.2.7.3. Europe
          • 5.2.7.3.1. Germany
          • 5.2.7.3.2. France
          • 5.2.7.3.3. Italy
          • 5.2.7.3.4. United Kingdom
          • 5.2.7.3.5. Netherlands
          • 5.2.7.3.6. Rest of Europe
        • 5.2.7.4. MEA
          • 5.2.7.4.1. Middle East
          • 5.2.7.4.2. Africa
        • 5.2.7.5. North America
          • 5.2.7.5.1. United States
          • 5.2.7.5.2. Canada
          • 5.2.7.5.3. Mexico
    • 5.3. Global Famotidine (Volume)
      • 5.3.1. Global Famotidine by: Type (Volume)
        • 5.3.1.1. Solution
        • 5.3.1.2. Tablet
      • 5.3.2. Global Famotidine by: Application (Volume)
        • 5.3.2.1. Medical
        • 5.3.2.2. Microbiology
        • 5.3.2.3. Others
      • 5.3.3. Global Famotidine by: Route of Administration (Volume)
        • 5.3.3.1. Oral
        • 5.3.3.2. Injection
      • 5.3.4. Global Famotidine by: Treatment (Volume)
        • 5.3.4.1. Zollinger-Ellison Syndrome
        • 5.3.4.2. Gastroesophageal Reflux Disorder (GERD)
        • 5.3.4.3. Erosive Esophagitis
        • 5.3.4.4. Other
      • 5.3.5. Global Famotidine by: Dosage (Volume)
        • 5.3.5.1. 0-10 mg
        • 5.3.5.2. Between 10-20 mg
        • 5.3.5.3. Above 20mg
      • 5.3.6. Global Famotidine by: End User (Volume)
        • 5.3.6.1. Adult
        • 5.3.6.2. Children
      • 5.3.7. Global Famotidine Region
        • 5.3.7.1. South America
          • 5.3.7.1.1. Brazil
          • 5.3.7.1.2. Argentina
          • 5.3.7.1.3. Rest of South America
        • 5.3.7.2. Asia Pacific
          • 5.3.7.2.1. China
          • 5.3.7.2.2. Japan
          • 5.3.7.2.3. India
          • 5.3.7.2.4. South Korea
          • 5.3.7.2.5. Taiwan
          • 5.3.7.2.6. Australia
          • 5.3.7.2.7. Rest of Asia-Pacific
        • 5.3.7.3. Europe
          • 5.3.7.3.1. Germany
          • 5.3.7.3.2. France
          • 5.3.7.3.3. Italy
          • 5.3.7.3.4. United Kingdom
          • 5.3.7.3.5. Netherlands
          • 5.3.7.3.6. Rest of Europe
        • 5.3.7.4. MEA
          • 5.3.7.4.1. Middle East
          • 5.3.7.4.2. Africa
        • 5.3.7.5. North America
          • 5.3.7.5.1. United States
          • 5.3.7.5.2. Canada
          • 5.3.7.5.3. Mexico
    • 5.4. Global Famotidine (Price)
      • 5.4.1. Global Famotidine by: Type (Price)
  • 6. Famotidine: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Uquifa (Spain)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Rakshit Drugs Private Limited (India)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Chempro Pharma (India)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Gauri Fine Chemicals (India)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Darou Pakhsh Pharma Chem Co. (Iran)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Pat Impex (India)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Wuhan Jayusion Pharmaceutical Technology Co., Ltd (China)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Phalanx Labs (India)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Teva Pharmaceuticals (United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Aurobindo Pharma (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
      • 6.4.11. Alembic Pharmaceuticals Inc (United States)
        • 6.4.11.1. Business Overview
        • 6.4.11.2. Products/Services Offerings
        • 6.4.11.3. Financial Analysis
        • 6.4.11.4. SWOT Analysis
      • 6.4.12. Mylan Laboratories Ltd. (United States)
        • 6.4.12.1. Business Overview
        • 6.4.12.2. Products/Services Offerings
        • 6.4.12.3. Financial Analysis
        • 6.4.12.4. SWOT Analysis
      • 6.4.13. Ercros (Spain)
        • 6.4.13.1. Business Overview
        • 6.4.13.2. Products/Services Offerings
        • 6.4.13.3. Financial Analysis
        • 6.4.13.4. SWOT Analysis
      • 6.4.14. Jeil Pharmaceutical (South Korea)
        • 6.4.14.1. Business Overview
        • 6.4.14.2. Products/Services Offerings
        • 6.4.14.3. Financial Analysis
        • 6.4.14.4. SWOT Analysis
  • 7. Global Famotidine Sale, by Type, Application, Route of Administration, Treatment, Dosage, End User and Region (value, volume and price ) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Famotidine (Value)
      • 7.2.1. Global Famotidine by: Type (Value)
        • 7.2.1.1. Solution
        • 7.2.1.2. Tablet
      • 7.2.2. Global Famotidine by: Application (Value)
        • 7.2.2.1. Medical
        • 7.2.2.2. Microbiology
        • 7.2.2.3. Others
      • 7.2.3. Global Famotidine by: Route of Administration (Value)
        • 7.2.3.1. Oral
        • 7.2.3.2. Injection
      • 7.2.4. Global Famotidine by: Treatment (Value)
        • 7.2.4.1. Zollinger-Ellison Syndrome
        • 7.2.4.2. Gastroesophageal Reflux Disorder (GERD)
        • 7.2.4.3. Erosive Esophagitis
        • 7.2.4.4. Other
      • 7.2.5. Global Famotidine by: Dosage (Value)
        • 7.2.5.1. 0-10 mg
        • 7.2.5.2. Between 10-20 mg
        • 7.2.5.3. Above 20mg
      • 7.2.6. Global Famotidine by: End User (Value)
        • 7.2.6.1. Adult
        • 7.2.6.2. Children
      • 7.2.7. Global Famotidine Region
        • 7.2.7.1. South America
          • 7.2.7.1.1. Brazil
          • 7.2.7.1.2. Argentina
          • 7.2.7.1.3. Rest of South America
        • 7.2.7.2. Asia Pacific
          • 7.2.7.2.1. China
          • 7.2.7.2.2. Japan
          • 7.2.7.2.3. India
          • 7.2.7.2.4. South Korea
          • 7.2.7.2.5. Taiwan
          • 7.2.7.2.6. Australia
          • 7.2.7.2.7. Rest of Asia-Pacific
        • 7.2.7.3. Europe
          • 7.2.7.3.1. Germany
          • 7.2.7.3.2. France
          • 7.2.7.3.3. Italy
          • 7.2.7.3.4. United Kingdom
          • 7.2.7.3.5. Netherlands
          • 7.2.7.3.6. Rest of Europe
        • 7.2.7.4. MEA
          • 7.2.7.4.1. Middle East
          • 7.2.7.4.2. Africa
        • 7.2.7.5. North America
          • 7.2.7.5.1. United States
          • 7.2.7.5.2. Canada
          • 7.2.7.5.3. Mexico
    • 7.3. Global Famotidine (Volume)
      • 7.3.1. Global Famotidine by: Type (Volume)
        • 7.3.1.1. Solution
        • 7.3.1.2. Tablet
      • 7.3.2. Global Famotidine by: Application (Volume)
        • 7.3.2.1. Medical
        • 7.3.2.2. Microbiology
        • 7.3.2.3. Others
      • 7.3.3. Global Famotidine by: Route of Administration (Volume)
        • 7.3.3.1. Oral
        • 7.3.3.2. Injection
      • 7.3.4. Global Famotidine by: Treatment (Volume)
        • 7.3.4.1. Zollinger-Ellison Syndrome
        • 7.3.4.2. Gastroesophageal Reflux Disorder (GERD)
        • 7.3.4.3. Erosive Esophagitis
        • 7.3.4.4. Other
      • 7.3.5. Global Famotidine by: Dosage (Volume)
        • 7.3.5.1. 0-10 mg
        • 7.3.5.2. Between 10-20 mg
        • 7.3.5.3. Above 20mg
      • 7.3.6. Global Famotidine by: End User (Volume)
        • 7.3.6.1. Adult
        • 7.3.6.2. Children
      • 7.3.7. Global Famotidine Region
        • 7.3.7.1. South America
          • 7.3.7.1.1. Brazil
          • 7.3.7.1.2. Argentina
          • 7.3.7.1.3. Rest of South America
        • 7.3.7.2. Asia Pacific
          • 7.3.7.2.1. China
          • 7.3.7.2.2. Japan
          • 7.3.7.2.3. India
          • 7.3.7.2.4. South Korea
          • 7.3.7.2.5. Taiwan
          • 7.3.7.2.6. Australia
          • 7.3.7.2.7. Rest of Asia-Pacific
        • 7.3.7.3. Europe
          • 7.3.7.3.1. Germany
          • 7.3.7.3.2. France
          • 7.3.7.3.3. Italy
          • 7.3.7.3.4. United Kingdom
          • 7.3.7.3.5. Netherlands
          • 7.3.7.3.6. Rest of Europe
        • 7.3.7.4. MEA
          • 7.3.7.4.1. Middle East
          • 7.3.7.4.2. Africa
        • 7.3.7.5. North America
          • 7.3.7.5.1. United States
          • 7.3.7.5.2. Canada
          • 7.3.7.5.3. Mexico
    • 7.4. Global Famotidine (Price)
      • 7.4.1. Global Famotidine by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Famotidine: by Type(USD Million)
  • Table 2. Famotidine Solution , by Region USD Million (2018-2023)
  • Table 3. Famotidine Tablet , by Region USD Million (2018-2023)
  • Table 4. Famotidine: by Application(USD Million)
  • Table 5. Famotidine Medical , by Region USD Million (2018-2023)
  • Table 6. Famotidine Microbiology , by Region USD Million (2018-2023)
  • Table 7. Famotidine Others , by Region USD Million (2018-2023)
  • Table 8. Famotidine: by Route of Administration(USD Million)
  • Table 9. Famotidine Oral , by Region USD Million (2018-2023)
  • Table 10. Famotidine Injection , by Region USD Million (2018-2023)
  • Table 11. Famotidine: by Treatment(USD Million)
  • Table 12. Famotidine Zollinger-Ellison Syndrome , by Region USD Million (2018-2023)
  • Table 13. Famotidine Gastroesophageal Reflux Disorder (GERD) , by Region USD Million (2018-2023)
  • Table 14. Famotidine Erosive Esophagitis , by Region USD Million (2018-2023)
  • Table 15. Famotidine Other , by Region USD Million (2018-2023)
  • Table 16. Famotidine: by Dosage(USD Million)
  • Table 17. Famotidine 0-10 mg , by Region USD Million (2018-2023)
  • Table 18. Famotidine Between 10-20 mg , by Region USD Million (2018-2023)
  • Table 19. Famotidine Above 20mg , by Region USD Million (2018-2023)
  • Table 20. Famotidine: by End User(USD Million)
  • Table 21. Famotidine Adult , by Region USD Million (2018-2023)
  • Table 22. Famotidine Children , by Region USD Million (2018-2023)
  • Table 23. South America Famotidine, by Country USD Million (2018-2023)
  • Table 24. South America Famotidine, by Type USD Million (2018-2023)
  • Table 25. South America Famotidine, by Application USD Million (2018-2023)
  • Table 26. South America Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 27. South America Famotidine, by Treatment USD Million (2018-2023)
  • Table 28. South America Famotidine, by Dosage USD Million (2018-2023)
  • Table 29. South America Famotidine, by End User USD Million (2018-2023)
  • Table 30. Brazil Famotidine, by Type USD Million (2018-2023)
  • Table 31. Brazil Famotidine, by Application USD Million (2018-2023)
  • Table 32. Brazil Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 33. Brazil Famotidine, by Treatment USD Million (2018-2023)
  • Table 34. Brazil Famotidine, by Dosage USD Million (2018-2023)
  • Table 35. Brazil Famotidine, by End User USD Million (2018-2023)
  • Table 36. Argentina Famotidine, by Type USD Million (2018-2023)
  • Table 37. Argentina Famotidine, by Application USD Million (2018-2023)
  • Table 38. Argentina Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 39. Argentina Famotidine, by Treatment USD Million (2018-2023)
  • Table 40. Argentina Famotidine, by Dosage USD Million (2018-2023)
  • Table 41. Argentina Famotidine, by End User USD Million (2018-2023)
  • Table 42. Rest of South America Famotidine, by Type USD Million (2018-2023)
  • Table 43. Rest of South America Famotidine, by Application USD Million (2018-2023)
  • Table 44. Rest of South America Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 45. Rest of South America Famotidine, by Treatment USD Million (2018-2023)
  • Table 46. Rest of South America Famotidine, by Dosage USD Million (2018-2023)
  • Table 47. Rest of South America Famotidine, by End User USD Million (2018-2023)
  • Table 48. Asia Pacific Famotidine, by Country USD Million (2018-2023)
  • Table 49. Asia Pacific Famotidine, by Type USD Million (2018-2023)
  • Table 50. Asia Pacific Famotidine, by Application USD Million (2018-2023)
  • Table 51. Asia Pacific Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 52. Asia Pacific Famotidine, by Treatment USD Million (2018-2023)
  • Table 53. Asia Pacific Famotidine, by Dosage USD Million (2018-2023)
  • Table 54. Asia Pacific Famotidine, by End User USD Million (2018-2023)
  • Table 55. China Famotidine, by Type USD Million (2018-2023)
  • Table 56. China Famotidine, by Application USD Million (2018-2023)
  • Table 57. China Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 58. China Famotidine, by Treatment USD Million (2018-2023)
  • Table 59. China Famotidine, by Dosage USD Million (2018-2023)
  • Table 60. China Famotidine, by End User USD Million (2018-2023)
  • Table 61. Japan Famotidine, by Type USD Million (2018-2023)
  • Table 62. Japan Famotidine, by Application USD Million (2018-2023)
  • Table 63. Japan Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 64. Japan Famotidine, by Treatment USD Million (2018-2023)
  • Table 65. Japan Famotidine, by Dosage USD Million (2018-2023)
  • Table 66. Japan Famotidine, by End User USD Million (2018-2023)
  • Table 67. India Famotidine, by Type USD Million (2018-2023)
  • Table 68. India Famotidine, by Application USD Million (2018-2023)
  • Table 69. India Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 70. India Famotidine, by Treatment USD Million (2018-2023)
  • Table 71. India Famotidine, by Dosage USD Million (2018-2023)
  • Table 72. India Famotidine, by End User USD Million (2018-2023)
  • Table 73. South Korea Famotidine, by Type USD Million (2018-2023)
  • Table 74. South Korea Famotidine, by Application USD Million (2018-2023)
  • Table 75. South Korea Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 76. South Korea Famotidine, by Treatment USD Million (2018-2023)
  • Table 77. South Korea Famotidine, by Dosage USD Million (2018-2023)
  • Table 78. South Korea Famotidine, by End User USD Million (2018-2023)
  • Table 79. Taiwan Famotidine, by Type USD Million (2018-2023)
  • Table 80. Taiwan Famotidine, by Application USD Million (2018-2023)
  • Table 81. Taiwan Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 82. Taiwan Famotidine, by Treatment USD Million (2018-2023)
  • Table 83. Taiwan Famotidine, by Dosage USD Million (2018-2023)
  • Table 84. Taiwan Famotidine, by End User USD Million (2018-2023)
  • Table 85. Australia Famotidine, by Type USD Million (2018-2023)
  • Table 86. Australia Famotidine, by Application USD Million (2018-2023)
  • Table 87. Australia Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 88. Australia Famotidine, by Treatment USD Million (2018-2023)
  • Table 89. Australia Famotidine, by Dosage USD Million (2018-2023)
  • Table 90. Australia Famotidine, by End User USD Million (2018-2023)
  • Table 91. Rest of Asia-Pacific Famotidine, by Type USD Million (2018-2023)
  • Table 92. Rest of Asia-Pacific Famotidine, by Application USD Million (2018-2023)
  • Table 93. Rest of Asia-Pacific Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 94. Rest of Asia-Pacific Famotidine, by Treatment USD Million (2018-2023)
  • Table 95. Rest of Asia-Pacific Famotidine, by Dosage USD Million (2018-2023)
  • Table 96. Rest of Asia-Pacific Famotidine, by End User USD Million (2018-2023)
  • Table 97. Europe Famotidine, by Country USD Million (2018-2023)
  • Table 98. Europe Famotidine, by Type USD Million (2018-2023)
  • Table 99. Europe Famotidine, by Application USD Million (2018-2023)
  • Table 100. Europe Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 101. Europe Famotidine, by Treatment USD Million (2018-2023)
  • Table 102. Europe Famotidine, by Dosage USD Million (2018-2023)
  • Table 103. Europe Famotidine, by End User USD Million (2018-2023)
  • Table 104. Germany Famotidine, by Type USD Million (2018-2023)
  • Table 105. Germany Famotidine, by Application USD Million (2018-2023)
  • Table 106. Germany Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 107. Germany Famotidine, by Treatment USD Million (2018-2023)
  • Table 108. Germany Famotidine, by Dosage USD Million (2018-2023)
  • Table 109. Germany Famotidine, by End User USD Million (2018-2023)
  • Table 110. France Famotidine, by Type USD Million (2018-2023)
  • Table 111. France Famotidine, by Application USD Million (2018-2023)
  • Table 112. France Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 113. France Famotidine, by Treatment USD Million (2018-2023)
  • Table 114. France Famotidine, by Dosage USD Million (2018-2023)
  • Table 115. France Famotidine, by End User USD Million (2018-2023)
  • Table 116. Italy Famotidine, by Type USD Million (2018-2023)
  • Table 117. Italy Famotidine, by Application USD Million (2018-2023)
  • Table 118. Italy Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 119. Italy Famotidine, by Treatment USD Million (2018-2023)
  • Table 120. Italy Famotidine, by Dosage USD Million (2018-2023)
  • Table 121. Italy Famotidine, by End User USD Million (2018-2023)
  • Table 122. United Kingdom Famotidine, by Type USD Million (2018-2023)
  • Table 123. United Kingdom Famotidine, by Application USD Million (2018-2023)
  • Table 124. United Kingdom Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 125. United Kingdom Famotidine, by Treatment USD Million (2018-2023)
  • Table 126. United Kingdom Famotidine, by Dosage USD Million (2018-2023)
  • Table 127. United Kingdom Famotidine, by End User USD Million (2018-2023)
  • Table 128. Netherlands Famotidine, by Type USD Million (2018-2023)
  • Table 129. Netherlands Famotidine, by Application USD Million (2018-2023)
  • Table 130. Netherlands Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 131. Netherlands Famotidine, by Treatment USD Million (2018-2023)
  • Table 132. Netherlands Famotidine, by Dosage USD Million (2018-2023)
  • Table 133. Netherlands Famotidine, by End User USD Million (2018-2023)
  • Table 134. Rest of Europe Famotidine, by Type USD Million (2018-2023)
  • Table 135. Rest of Europe Famotidine, by Application USD Million (2018-2023)
  • Table 136. Rest of Europe Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 137. Rest of Europe Famotidine, by Treatment USD Million (2018-2023)
  • Table 138. Rest of Europe Famotidine, by Dosage USD Million (2018-2023)
  • Table 139. Rest of Europe Famotidine, by End User USD Million (2018-2023)
  • Table 140. MEA Famotidine, by Country USD Million (2018-2023)
  • Table 141. MEA Famotidine, by Type USD Million (2018-2023)
  • Table 142. MEA Famotidine, by Application USD Million (2018-2023)
  • Table 143. MEA Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 144. MEA Famotidine, by Treatment USD Million (2018-2023)
  • Table 145. MEA Famotidine, by Dosage USD Million (2018-2023)
  • Table 146. MEA Famotidine, by End User USD Million (2018-2023)
  • Table 147. Middle East Famotidine, by Type USD Million (2018-2023)
  • Table 148. Middle East Famotidine, by Application USD Million (2018-2023)
  • Table 149. Middle East Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 150. Middle East Famotidine, by Treatment USD Million (2018-2023)
  • Table 151. Middle East Famotidine, by Dosage USD Million (2018-2023)
  • Table 152. Middle East Famotidine, by End User USD Million (2018-2023)
  • Table 153. Africa Famotidine, by Type USD Million (2018-2023)
  • Table 154. Africa Famotidine, by Application USD Million (2018-2023)
  • Table 155. Africa Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 156. Africa Famotidine, by Treatment USD Million (2018-2023)
  • Table 157. Africa Famotidine, by Dosage USD Million (2018-2023)
  • Table 158. Africa Famotidine, by End User USD Million (2018-2023)
  • Table 159. North America Famotidine, by Country USD Million (2018-2023)
  • Table 160. North America Famotidine, by Type USD Million (2018-2023)
  • Table 161. North America Famotidine, by Application USD Million (2018-2023)
  • Table 162. North America Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 163. North America Famotidine, by Treatment USD Million (2018-2023)
  • Table 164. North America Famotidine, by Dosage USD Million (2018-2023)
  • Table 165. North America Famotidine, by End User USD Million (2018-2023)
  • Table 166. United States Famotidine, by Type USD Million (2018-2023)
  • Table 167. United States Famotidine, by Application USD Million (2018-2023)
  • Table 168. United States Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 169. United States Famotidine, by Treatment USD Million (2018-2023)
  • Table 170. United States Famotidine, by Dosage USD Million (2018-2023)
  • Table 171. United States Famotidine, by End User USD Million (2018-2023)
  • Table 172. Canada Famotidine, by Type USD Million (2018-2023)
  • Table 173. Canada Famotidine, by Application USD Million (2018-2023)
  • Table 174. Canada Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 175. Canada Famotidine, by Treatment USD Million (2018-2023)
  • Table 176. Canada Famotidine, by Dosage USD Million (2018-2023)
  • Table 177. Canada Famotidine, by End User USD Million (2018-2023)
  • Table 178. Mexico Famotidine, by Type USD Million (2018-2023)
  • Table 179. Mexico Famotidine, by Application USD Million (2018-2023)
  • Table 180. Mexico Famotidine, by Route of Administration USD Million (2018-2023)
  • Table 181. Mexico Famotidine, by Treatment USD Million (2018-2023)
  • Table 182. Mexico Famotidine, by Dosage USD Million (2018-2023)
  • Table 183. Mexico Famotidine, by End User USD Million (2018-2023)
  • Table 184. Famotidine Sales: by Type(Tons)
  • Table 185. Famotidine Sales Solution , by Region Tons (2018-2023)
  • Table 186. Famotidine Sales Tablet , by Region Tons (2018-2023)
  • Table 187. Famotidine Sales: by Application(Tons)
  • Table 188. Famotidine Sales Medical , by Region Tons (2018-2023)
  • Table 189. Famotidine Sales Microbiology , by Region Tons (2018-2023)
  • Table 190. Famotidine Sales Others , by Region Tons (2018-2023)
  • Table 191. Famotidine Sales: by Route of Administration(Tons)
  • Table 192. Famotidine Sales Oral , by Region Tons (2018-2023)
  • Table 193. Famotidine Sales Injection , by Region Tons (2018-2023)
  • Table 194. Famotidine Sales: by Treatment(Tons)
  • Table 195. Famotidine Sales Zollinger-Ellison Syndrome , by Region Tons (2018-2023)
  • Table 196. Famotidine Sales Gastroesophageal Reflux Disorder (GERD) , by Region Tons (2018-2023)
  • Table 197. Famotidine Sales Erosive Esophagitis , by Region Tons (2018-2023)
  • Table 198. Famotidine Sales Other , by Region Tons (2018-2023)
  • Table 199. Famotidine Sales: by Dosage(Tons)
  • Table 200. Famotidine Sales 0-10 mg , by Region Tons (2018-2023)
  • Table 201. Famotidine Sales Between 10-20 mg , by Region Tons (2018-2023)
  • Table 202. Famotidine Sales Above 20mg , by Region Tons (2018-2023)
  • Table 203. Famotidine Sales: by End User(Tons)
  • Table 204. Famotidine Sales Adult , by Region Tons (2018-2023)
  • Table 205. Famotidine Sales Children , by Region Tons (2018-2023)
  • Table 206. South America Famotidine Sales, by Country Tons (2018-2023)
  • Table 207. South America Famotidine Sales, by Type Tons (2018-2023)
  • Table 208. South America Famotidine Sales, by Application Tons (2018-2023)
  • Table 209. South America Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 210. South America Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 211. South America Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 212. South America Famotidine Sales, by End User Tons (2018-2023)
  • Table 213. Brazil Famotidine Sales, by Type Tons (2018-2023)
  • Table 214. Brazil Famotidine Sales, by Application Tons (2018-2023)
  • Table 215. Brazil Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 216. Brazil Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 217. Brazil Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 218. Brazil Famotidine Sales, by End User Tons (2018-2023)
  • Table 219. Argentina Famotidine Sales, by Type Tons (2018-2023)
  • Table 220. Argentina Famotidine Sales, by Application Tons (2018-2023)
  • Table 221. Argentina Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 222. Argentina Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 223. Argentina Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 224. Argentina Famotidine Sales, by End User Tons (2018-2023)
  • Table 225. Rest of South America Famotidine Sales, by Type Tons (2018-2023)
  • Table 226. Rest of South America Famotidine Sales, by Application Tons (2018-2023)
  • Table 227. Rest of South America Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 228. Rest of South America Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 229. Rest of South America Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 230. Rest of South America Famotidine Sales, by End User Tons (2018-2023)
  • Table 231. Asia Pacific Famotidine Sales, by Country Tons (2018-2023)
  • Table 232. Asia Pacific Famotidine Sales, by Type Tons (2018-2023)
  • Table 233. Asia Pacific Famotidine Sales, by Application Tons (2018-2023)
  • Table 234. Asia Pacific Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 235. Asia Pacific Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 236. Asia Pacific Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 237. Asia Pacific Famotidine Sales, by End User Tons (2018-2023)
  • Table 238. China Famotidine Sales, by Type Tons (2018-2023)
  • Table 239. China Famotidine Sales, by Application Tons (2018-2023)
  • Table 240. China Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 241. China Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 242. China Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 243. China Famotidine Sales, by End User Tons (2018-2023)
  • Table 244. Japan Famotidine Sales, by Type Tons (2018-2023)
  • Table 245. Japan Famotidine Sales, by Application Tons (2018-2023)
  • Table 246. Japan Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 247. Japan Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 248. Japan Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 249. Japan Famotidine Sales, by End User Tons (2018-2023)
  • Table 250. India Famotidine Sales, by Type Tons (2018-2023)
  • Table 251. India Famotidine Sales, by Application Tons (2018-2023)
  • Table 252. India Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 253. India Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 254. India Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 255. India Famotidine Sales, by End User Tons (2018-2023)
  • Table 256. South Korea Famotidine Sales, by Type Tons (2018-2023)
  • Table 257. South Korea Famotidine Sales, by Application Tons (2018-2023)
  • Table 258. South Korea Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 259. South Korea Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 260. South Korea Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 261. South Korea Famotidine Sales, by End User Tons (2018-2023)
  • Table 262. Taiwan Famotidine Sales, by Type Tons (2018-2023)
  • Table 263. Taiwan Famotidine Sales, by Application Tons (2018-2023)
  • Table 264. Taiwan Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 265. Taiwan Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 266. Taiwan Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 267. Taiwan Famotidine Sales, by End User Tons (2018-2023)
  • Table 268. Australia Famotidine Sales, by Type Tons (2018-2023)
  • Table 269. Australia Famotidine Sales, by Application Tons (2018-2023)
  • Table 270. Australia Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 271. Australia Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 272. Australia Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 273. Australia Famotidine Sales, by End User Tons (2018-2023)
  • Table 274. Rest of Asia-Pacific Famotidine Sales, by Type Tons (2018-2023)
  • Table 275. Rest of Asia-Pacific Famotidine Sales, by Application Tons (2018-2023)
  • Table 276. Rest of Asia-Pacific Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 277. Rest of Asia-Pacific Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 278. Rest of Asia-Pacific Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 279. Rest of Asia-Pacific Famotidine Sales, by End User Tons (2018-2023)
  • Table 280. Europe Famotidine Sales, by Country Tons (2018-2023)
  • Table 281. Europe Famotidine Sales, by Type Tons (2018-2023)
  • Table 282. Europe Famotidine Sales, by Application Tons (2018-2023)
  • Table 283. Europe Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 284. Europe Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 285. Europe Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 286. Europe Famotidine Sales, by End User Tons (2018-2023)
  • Table 287. Germany Famotidine Sales, by Type Tons (2018-2023)
  • Table 288. Germany Famotidine Sales, by Application Tons (2018-2023)
  • Table 289. Germany Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 290. Germany Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 291. Germany Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 292. Germany Famotidine Sales, by End User Tons (2018-2023)
  • Table 293. France Famotidine Sales, by Type Tons (2018-2023)
  • Table 294. France Famotidine Sales, by Application Tons (2018-2023)
  • Table 295. France Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 296. France Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 297. France Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 298. France Famotidine Sales, by End User Tons (2018-2023)
  • Table 299. Italy Famotidine Sales, by Type Tons (2018-2023)
  • Table 300. Italy Famotidine Sales, by Application Tons (2018-2023)
  • Table 301. Italy Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 302. Italy Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 303. Italy Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 304. Italy Famotidine Sales, by End User Tons (2018-2023)
  • Table 305. United Kingdom Famotidine Sales, by Type Tons (2018-2023)
  • Table 306. United Kingdom Famotidine Sales, by Application Tons (2018-2023)
  • Table 307. United Kingdom Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 308. United Kingdom Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 309. United Kingdom Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 310. United Kingdom Famotidine Sales, by End User Tons (2018-2023)
  • Table 311. Netherlands Famotidine Sales, by Type Tons (2018-2023)
  • Table 312. Netherlands Famotidine Sales, by Application Tons (2018-2023)
  • Table 313. Netherlands Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 314. Netherlands Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 315. Netherlands Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 316. Netherlands Famotidine Sales, by End User Tons (2018-2023)
  • Table 317. Rest of Europe Famotidine Sales, by Type Tons (2018-2023)
  • Table 318. Rest of Europe Famotidine Sales, by Application Tons (2018-2023)
  • Table 319. Rest of Europe Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 320. Rest of Europe Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 321. Rest of Europe Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 322. Rest of Europe Famotidine Sales, by End User Tons (2018-2023)
  • Table 323. MEA Famotidine Sales, by Country Tons (2018-2023)
  • Table 324. MEA Famotidine Sales, by Type Tons (2018-2023)
  • Table 325. MEA Famotidine Sales, by Application Tons (2018-2023)
  • Table 326. MEA Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 327. MEA Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 328. MEA Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 329. MEA Famotidine Sales, by End User Tons (2018-2023)
  • Table 330. Middle East Famotidine Sales, by Type Tons (2018-2023)
  • Table 331. Middle East Famotidine Sales, by Application Tons (2018-2023)
  • Table 332. Middle East Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 333. Middle East Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 334. Middle East Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 335. Middle East Famotidine Sales, by End User Tons (2018-2023)
  • Table 336. Africa Famotidine Sales, by Type Tons (2018-2023)
  • Table 337. Africa Famotidine Sales, by Application Tons (2018-2023)
  • Table 338. Africa Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 339. Africa Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 340. Africa Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 341. Africa Famotidine Sales, by End User Tons (2018-2023)
  • Table 342. North America Famotidine Sales, by Country Tons (2018-2023)
  • Table 343. North America Famotidine Sales, by Type Tons (2018-2023)
  • Table 344. North America Famotidine Sales, by Application Tons (2018-2023)
  • Table 345. North America Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 346. North America Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 347. North America Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 348. North America Famotidine Sales, by End User Tons (2018-2023)
  • Table 349. United States Famotidine Sales, by Type Tons (2018-2023)
  • Table 350. United States Famotidine Sales, by Application Tons (2018-2023)
  • Table 351. United States Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 352. United States Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 353. United States Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 354. United States Famotidine Sales, by End User Tons (2018-2023)
  • Table 355. Canada Famotidine Sales, by Type Tons (2018-2023)
  • Table 356. Canada Famotidine Sales, by Application Tons (2018-2023)
  • Table 357. Canada Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 358. Canada Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 359. Canada Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 360. Canada Famotidine Sales, by End User Tons (2018-2023)
  • Table 361. Mexico Famotidine Sales, by Type Tons (2018-2023)
  • Table 362. Mexico Famotidine Sales, by Application Tons (2018-2023)
  • Table 363. Mexico Famotidine Sales, by Route of Administration Tons (2018-2023)
  • Table 364. Mexico Famotidine Sales, by Treatment Tons (2018-2023)
  • Table 365. Mexico Famotidine Sales, by Dosage Tons (2018-2023)
  • Table 366. Mexico Famotidine Sales, by End User Tons (2018-2023)
  • Table 367. Famotidine: by Type(USD/Units)
  • Table 368. Company Basic Information, Sales Area and Its Competitors
  • Table 369. Company Basic Information, Sales Area and Its Competitors
  • Table 370. Company Basic Information, Sales Area and Its Competitors
  • Table 371. Company Basic Information, Sales Area and Its Competitors
  • Table 372. Company Basic Information, Sales Area and Its Competitors
  • Table 373. Company Basic Information, Sales Area and Its Competitors
  • Table 374. Company Basic Information, Sales Area and Its Competitors
  • Table 375. Company Basic Information, Sales Area and Its Competitors
  • Table 376. Company Basic Information, Sales Area and Its Competitors
  • Table 377. Company Basic Information, Sales Area and Its Competitors
  • Table 378. Company Basic Information, Sales Area and Its Competitors
  • Table 379. Company Basic Information, Sales Area and Its Competitors
  • Table 380. Company Basic Information, Sales Area and Its Competitors
  • Table 381. Company Basic Information, Sales Area and Its Competitors
  • Table 382. Famotidine: by Type(USD Million)
  • Table 383. Famotidine Solution , by Region USD Million (2025-2030)
  • Table 384. Famotidine Tablet , by Region USD Million (2025-2030)
  • Table 385. Famotidine: by Application(USD Million)
  • Table 386. Famotidine Medical , by Region USD Million (2025-2030)
  • Table 387. Famotidine Microbiology , by Region USD Million (2025-2030)
  • Table 388. Famotidine Others , by Region USD Million (2025-2030)
  • Table 389. Famotidine: by Route of Administration(USD Million)
  • Table 390. Famotidine Oral , by Region USD Million (2025-2030)
  • Table 391. Famotidine Injection , by Region USD Million (2025-2030)
  • Table 392. Famotidine: by Treatment(USD Million)
  • Table 393. Famotidine Zollinger-Ellison Syndrome , by Region USD Million (2025-2030)
  • Table 394. Famotidine Gastroesophageal Reflux Disorder (GERD) , by Region USD Million (2025-2030)
  • Table 395. Famotidine Erosive Esophagitis , by Region USD Million (2025-2030)
  • Table 396. Famotidine Other , by Region USD Million (2025-2030)
  • Table 397. Famotidine: by Dosage(USD Million)
  • Table 398. Famotidine 0-10 mg , by Region USD Million (2025-2030)
  • Table 399. Famotidine Between 10-20 mg , by Region USD Million (2025-2030)
  • Table 400. Famotidine Above 20mg , by Region USD Million (2025-2030)
  • Table 401. Famotidine: by End User(USD Million)
  • Table 402. Famotidine Adult , by Region USD Million (2025-2030)
  • Table 403. Famotidine Children , by Region USD Million (2025-2030)
  • Table 404. South America Famotidine, by Country USD Million (2025-2030)
  • Table 405. South America Famotidine, by Type USD Million (2025-2030)
  • Table 406. South America Famotidine, by Application USD Million (2025-2030)
  • Table 407. South America Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 408. South America Famotidine, by Treatment USD Million (2025-2030)
  • Table 409. South America Famotidine, by Dosage USD Million (2025-2030)
  • Table 410. South America Famotidine, by End User USD Million (2025-2030)
  • Table 411. Brazil Famotidine, by Type USD Million (2025-2030)
  • Table 412. Brazil Famotidine, by Application USD Million (2025-2030)
  • Table 413. Brazil Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 414. Brazil Famotidine, by Treatment USD Million (2025-2030)
  • Table 415. Brazil Famotidine, by Dosage USD Million (2025-2030)
  • Table 416. Brazil Famotidine, by End User USD Million (2025-2030)
  • Table 417. Argentina Famotidine, by Type USD Million (2025-2030)
  • Table 418. Argentina Famotidine, by Application USD Million (2025-2030)
  • Table 419. Argentina Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 420. Argentina Famotidine, by Treatment USD Million (2025-2030)
  • Table 421. Argentina Famotidine, by Dosage USD Million (2025-2030)
  • Table 422. Argentina Famotidine, by End User USD Million (2025-2030)
  • Table 423. Rest of South America Famotidine, by Type USD Million (2025-2030)
  • Table 424. Rest of South America Famotidine, by Application USD Million (2025-2030)
  • Table 425. Rest of South America Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 426. Rest of South America Famotidine, by Treatment USD Million (2025-2030)
  • Table 427. Rest of South America Famotidine, by Dosage USD Million (2025-2030)
  • Table 428. Rest of South America Famotidine, by End User USD Million (2025-2030)
  • Table 429. Asia Pacific Famotidine, by Country USD Million (2025-2030)
  • Table 430. Asia Pacific Famotidine, by Type USD Million (2025-2030)
  • Table 431. Asia Pacific Famotidine, by Application USD Million (2025-2030)
  • Table 432. Asia Pacific Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 433. Asia Pacific Famotidine, by Treatment USD Million (2025-2030)
  • Table 434. Asia Pacific Famotidine, by Dosage USD Million (2025-2030)
  • Table 435. Asia Pacific Famotidine, by End User USD Million (2025-2030)
  • Table 436. China Famotidine, by Type USD Million (2025-2030)
  • Table 437. China Famotidine, by Application USD Million (2025-2030)
  • Table 438. China Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 439. China Famotidine, by Treatment USD Million (2025-2030)
  • Table 440. China Famotidine, by Dosage USD Million (2025-2030)
  • Table 441. China Famotidine, by End User USD Million (2025-2030)
  • Table 442. Japan Famotidine, by Type USD Million (2025-2030)
  • Table 443. Japan Famotidine, by Application USD Million (2025-2030)
  • Table 444. Japan Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 445. Japan Famotidine, by Treatment USD Million (2025-2030)
  • Table 446. Japan Famotidine, by Dosage USD Million (2025-2030)
  • Table 447. Japan Famotidine, by End User USD Million (2025-2030)
  • Table 448. India Famotidine, by Type USD Million (2025-2030)
  • Table 449. India Famotidine, by Application USD Million (2025-2030)
  • Table 450. India Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 451. India Famotidine, by Treatment USD Million (2025-2030)
  • Table 452. India Famotidine, by Dosage USD Million (2025-2030)
  • Table 453. India Famotidine, by End User USD Million (2025-2030)
  • Table 454. South Korea Famotidine, by Type USD Million (2025-2030)
  • Table 455. South Korea Famotidine, by Application USD Million (2025-2030)
  • Table 456. South Korea Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 457. South Korea Famotidine, by Treatment USD Million (2025-2030)
  • Table 458. South Korea Famotidine, by Dosage USD Million (2025-2030)
  • Table 459. South Korea Famotidine, by End User USD Million (2025-2030)
  • Table 460. Taiwan Famotidine, by Type USD Million (2025-2030)
  • Table 461. Taiwan Famotidine, by Application USD Million (2025-2030)
  • Table 462. Taiwan Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 463. Taiwan Famotidine, by Treatment USD Million (2025-2030)
  • Table 464. Taiwan Famotidine, by Dosage USD Million (2025-2030)
  • Table 465. Taiwan Famotidine, by End User USD Million (2025-2030)
  • Table 466. Australia Famotidine, by Type USD Million (2025-2030)
  • Table 467. Australia Famotidine, by Application USD Million (2025-2030)
  • Table 468. Australia Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 469. Australia Famotidine, by Treatment USD Million (2025-2030)
  • Table 470. Australia Famotidine, by Dosage USD Million (2025-2030)
  • Table 471. Australia Famotidine, by End User USD Million (2025-2030)
  • Table 472. Rest of Asia-Pacific Famotidine, by Type USD Million (2025-2030)
  • Table 473. Rest of Asia-Pacific Famotidine, by Application USD Million (2025-2030)
  • Table 474. Rest of Asia-Pacific Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 475. Rest of Asia-Pacific Famotidine, by Treatment USD Million (2025-2030)
  • Table 476. Rest of Asia-Pacific Famotidine, by Dosage USD Million (2025-2030)
  • Table 477. Rest of Asia-Pacific Famotidine, by End User USD Million (2025-2030)
  • Table 478. Europe Famotidine, by Country USD Million (2025-2030)
  • Table 479. Europe Famotidine, by Type USD Million (2025-2030)
  • Table 480. Europe Famotidine, by Application USD Million (2025-2030)
  • Table 481. Europe Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 482. Europe Famotidine, by Treatment USD Million (2025-2030)
  • Table 483. Europe Famotidine, by Dosage USD Million (2025-2030)
  • Table 484. Europe Famotidine, by End User USD Million (2025-2030)
  • Table 485. Germany Famotidine, by Type USD Million (2025-2030)
  • Table 486. Germany Famotidine, by Application USD Million (2025-2030)
  • Table 487. Germany Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 488. Germany Famotidine, by Treatment USD Million (2025-2030)
  • Table 489. Germany Famotidine, by Dosage USD Million (2025-2030)
  • Table 490. Germany Famotidine, by End User USD Million (2025-2030)
  • Table 491. France Famotidine, by Type USD Million (2025-2030)
  • Table 492. France Famotidine, by Application USD Million (2025-2030)
  • Table 493. France Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 494. France Famotidine, by Treatment USD Million (2025-2030)
  • Table 495. France Famotidine, by Dosage USD Million (2025-2030)
  • Table 496. France Famotidine, by End User USD Million (2025-2030)
  • Table 497. Italy Famotidine, by Type USD Million (2025-2030)
  • Table 498. Italy Famotidine, by Application USD Million (2025-2030)
  • Table 499. Italy Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 500. Italy Famotidine, by Treatment USD Million (2025-2030)
  • Table 501. Italy Famotidine, by Dosage USD Million (2025-2030)
  • Table 502. Italy Famotidine, by End User USD Million (2025-2030)
  • Table 503. United Kingdom Famotidine, by Type USD Million (2025-2030)
  • Table 504. United Kingdom Famotidine, by Application USD Million (2025-2030)
  • Table 505. United Kingdom Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 506. United Kingdom Famotidine, by Treatment USD Million (2025-2030)
  • Table 507. United Kingdom Famotidine, by Dosage USD Million (2025-2030)
  • Table 508. United Kingdom Famotidine, by End User USD Million (2025-2030)
  • Table 509. Netherlands Famotidine, by Type USD Million (2025-2030)
  • Table 510. Netherlands Famotidine, by Application USD Million (2025-2030)
  • Table 511. Netherlands Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 512. Netherlands Famotidine, by Treatment USD Million (2025-2030)
  • Table 513. Netherlands Famotidine, by Dosage USD Million (2025-2030)
  • Table 514. Netherlands Famotidine, by End User USD Million (2025-2030)
  • Table 515. Rest of Europe Famotidine, by Type USD Million (2025-2030)
  • Table 516. Rest of Europe Famotidine, by Application USD Million (2025-2030)
  • Table 517. Rest of Europe Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 518. Rest of Europe Famotidine, by Treatment USD Million (2025-2030)
  • Table 519. Rest of Europe Famotidine, by Dosage USD Million (2025-2030)
  • Table 520. Rest of Europe Famotidine, by End User USD Million (2025-2030)
  • Table 521. MEA Famotidine, by Country USD Million (2025-2030)
  • Table 522. MEA Famotidine, by Type USD Million (2025-2030)
  • Table 523. MEA Famotidine, by Application USD Million (2025-2030)
  • Table 524. MEA Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 525. MEA Famotidine, by Treatment USD Million (2025-2030)
  • Table 526. MEA Famotidine, by Dosage USD Million (2025-2030)
  • Table 527. MEA Famotidine, by End User USD Million (2025-2030)
  • Table 528. Middle East Famotidine, by Type USD Million (2025-2030)
  • Table 529. Middle East Famotidine, by Application USD Million (2025-2030)
  • Table 530. Middle East Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 531. Middle East Famotidine, by Treatment USD Million (2025-2030)
  • Table 532. Middle East Famotidine, by Dosage USD Million (2025-2030)
  • Table 533. Middle East Famotidine, by End User USD Million (2025-2030)
  • Table 534. Africa Famotidine, by Type USD Million (2025-2030)
  • Table 535. Africa Famotidine, by Application USD Million (2025-2030)
  • Table 536. Africa Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 537. Africa Famotidine, by Treatment USD Million (2025-2030)
  • Table 538. Africa Famotidine, by Dosage USD Million (2025-2030)
  • Table 539. Africa Famotidine, by End User USD Million (2025-2030)
  • Table 540. North America Famotidine, by Country USD Million (2025-2030)
  • Table 541. North America Famotidine, by Type USD Million (2025-2030)
  • Table 542. North America Famotidine, by Application USD Million (2025-2030)
  • Table 543. North America Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 544. North America Famotidine, by Treatment USD Million (2025-2030)
  • Table 545. North America Famotidine, by Dosage USD Million (2025-2030)
  • Table 546. North America Famotidine, by End User USD Million (2025-2030)
  • Table 547. United States Famotidine, by Type USD Million (2025-2030)
  • Table 548. United States Famotidine, by Application USD Million (2025-2030)
  • Table 549. United States Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 550. United States Famotidine, by Treatment USD Million (2025-2030)
  • Table 551. United States Famotidine, by Dosage USD Million (2025-2030)
  • Table 552. United States Famotidine, by End User USD Million (2025-2030)
  • Table 553. Canada Famotidine, by Type USD Million (2025-2030)
  • Table 554. Canada Famotidine, by Application USD Million (2025-2030)
  • Table 555. Canada Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 556. Canada Famotidine, by Treatment USD Million (2025-2030)
  • Table 557. Canada Famotidine, by Dosage USD Million (2025-2030)
  • Table 558. Canada Famotidine, by End User USD Million (2025-2030)
  • Table 559. Mexico Famotidine, by Type USD Million (2025-2030)
  • Table 560. Mexico Famotidine, by Application USD Million (2025-2030)
  • Table 561. Mexico Famotidine, by Route of Administration USD Million (2025-2030)
  • Table 562. Mexico Famotidine, by Treatment USD Million (2025-2030)
  • Table 563. Mexico Famotidine, by Dosage USD Million (2025-2030)
  • Table 564. Mexico Famotidine, by End User USD Million (2025-2030)
  • Table 565. Famotidine Sales: by Type(Tons)
  • Table 566. Famotidine Sales Solution , by Region Tons (2025-2030)
  • Table 567. Famotidine Sales Tablet , by Region Tons (2025-2030)
  • Table 568. Famotidine Sales: by Application(Tons)
  • Table 569. Famotidine Sales Medical , by Region Tons (2025-2030)
  • Table 570. Famotidine Sales Microbiology , by Region Tons (2025-2030)
  • Table 571. Famotidine Sales Others , by Region Tons (2025-2030)
  • Table 572. Famotidine Sales: by Route of Administration(Tons)
  • Table 573. Famotidine Sales Oral , by Region Tons (2025-2030)
  • Table 574. Famotidine Sales Injection , by Region Tons (2025-2030)
  • Table 575. Famotidine Sales: by Treatment(Tons)
  • Table 576. Famotidine Sales Zollinger-Ellison Syndrome , by Region Tons (2025-2030)
  • Table 577. Famotidine Sales Gastroesophageal Reflux Disorder (GERD) , by Region Tons (2025-2030)
  • Table 578. Famotidine Sales Erosive Esophagitis , by Region Tons (2025-2030)
  • Table 579. Famotidine Sales Other , by Region Tons (2025-2030)
  • Table 580. Famotidine Sales: by Dosage(Tons)
  • Table 581. Famotidine Sales 0-10 mg , by Region Tons (2025-2030)
  • Table 582. Famotidine Sales Between 10-20 mg , by Region Tons (2025-2030)
  • Table 583. Famotidine Sales Above 20mg , by Region Tons (2025-2030)
  • Table 584. Famotidine Sales: by End User(Tons)
  • Table 585. Famotidine Sales Adult , by Region Tons (2025-2030)
  • Table 586. Famotidine Sales Children , by Region Tons (2025-2030)
  • Table 587. South America Famotidine Sales, by Country Tons (2025-2030)
  • Table 588. South America Famotidine Sales, by Type Tons (2025-2030)
  • Table 589. South America Famotidine Sales, by Application Tons (2025-2030)
  • Table 590. South America Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 591. South America Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 592. South America Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 593. South America Famotidine Sales, by End User Tons (2025-2030)
  • Table 594. Brazil Famotidine Sales, by Type Tons (2025-2030)
  • Table 595. Brazil Famotidine Sales, by Application Tons (2025-2030)
  • Table 596. Brazil Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 597. Brazil Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 598. Brazil Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 599. Brazil Famotidine Sales, by End User Tons (2025-2030)
  • Table 600. Argentina Famotidine Sales, by Type Tons (2025-2030)
  • Table 601. Argentina Famotidine Sales, by Application Tons (2025-2030)
  • Table 602. Argentina Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 603. Argentina Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 604. Argentina Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 605. Argentina Famotidine Sales, by End User Tons (2025-2030)
  • Table 606. Rest of South America Famotidine Sales, by Type Tons (2025-2030)
  • Table 607. Rest of South America Famotidine Sales, by Application Tons (2025-2030)
  • Table 608. Rest of South America Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 609. Rest of South America Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 610. Rest of South America Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 611. Rest of South America Famotidine Sales, by End User Tons (2025-2030)
  • Table 612. Asia Pacific Famotidine Sales, by Country Tons (2025-2030)
  • Table 613. Asia Pacific Famotidine Sales, by Type Tons (2025-2030)
  • Table 614. Asia Pacific Famotidine Sales, by Application Tons (2025-2030)
  • Table 615. Asia Pacific Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 616. Asia Pacific Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 617. Asia Pacific Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 618. Asia Pacific Famotidine Sales, by End User Tons (2025-2030)
  • Table 619. China Famotidine Sales, by Type Tons (2025-2030)
  • Table 620. China Famotidine Sales, by Application Tons (2025-2030)
  • Table 621. China Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 622. China Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 623. China Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 624. China Famotidine Sales, by End User Tons (2025-2030)
  • Table 625. Japan Famotidine Sales, by Type Tons (2025-2030)
  • Table 626. Japan Famotidine Sales, by Application Tons (2025-2030)
  • Table 627. Japan Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 628. Japan Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 629. Japan Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 630. Japan Famotidine Sales, by End User Tons (2025-2030)
  • Table 631. India Famotidine Sales, by Type Tons (2025-2030)
  • Table 632. India Famotidine Sales, by Application Tons (2025-2030)
  • Table 633. India Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 634. India Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 635. India Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 636. India Famotidine Sales, by End User Tons (2025-2030)
  • Table 637. South Korea Famotidine Sales, by Type Tons (2025-2030)
  • Table 638. South Korea Famotidine Sales, by Application Tons (2025-2030)
  • Table 639. South Korea Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 640. South Korea Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 641. South Korea Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 642. South Korea Famotidine Sales, by End User Tons (2025-2030)
  • Table 643. Taiwan Famotidine Sales, by Type Tons (2025-2030)
  • Table 644. Taiwan Famotidine Sales, by Application Tons (2025-2030)
  • Table 645. Taiwan Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 646. Taiwan Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 647. Taiwan Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 648. Taiwan Famotidine Sales, by End User Tons (2025-2030)
  • Table 649. Australia Famotidine Sales, by Type Tons (2025-2030)
  • Table 650. Australia Famotidine Sales, by Application Tons (2025-2030)
  • Table 651. Australia Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 652. Australia Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 653. Australia Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 654. Australia Famotidine Sales, by End User Tons (2025-2030)
  • Table 655. Rest of Asia-Pacific Famotidine Sales, by Type Tons (2025-2030)
  • Table 656. Rest of Asia-Pacific Famotidine Sales, by Application Tons (2025-2030)
  • Table 657. Rest of Asia-Pacific Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 658. Rest of Asia-Pacific Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 659. Rest of Asia-Pacific Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 660. Rest of Asia-Pacific Famotidine Sales, by End User Tons (2025-2030)
  • Table 661. Europe Famotidine Sales, by Country Tons (2025-2030)
  • Table 662. Europe Famotidine Sales, by Type Tons (2025-2030)
  • Table 663. Europe Famotidine Sales, by Application Tons (2025-2030)
  • Table 664. Europe Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 665. Europe Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 666. Europe Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 667. Europe Famotidine Sales, by End User Tons (2025-2030)
  • Table 668. Germany Famotidine Sales, by Type Tons (2025-2030)
  • Table 669. Germany Famotidine Sales, by Application Tons (2025-2030)
  • Table 670. Germany Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 671. Germany Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 672. Germany Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 673. Germany Famotidine Sales, by End User Tons (2025-2030)
  • Table 674. France Famotidine Sales, by Type Tons (2025-2030)
  • Table 675. France Famotidine Sales, by Application Tons (2025-2030)
  • Table 676. France Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 677. France Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 678. France Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 679. France Famotidine Sales, by End User Tons (2025-2030)
  • Table 680. Italy Famotidine Sales, by Type Tons (2025-2030)
  • Table 681. Italy Famotidine Sales, by Application Tons (2025-2030)
  • Table 682. Italy Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 683. Italy Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 684. Italy Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 685. Italy Famotidine Sales, by End User Tons (2025-2030)
  • Table 686. United Kingdom Famotidine Sales, by Type Tons (2025-2030)
  • Table 687. United Kingdom Famotidine Sales, by Application Tons (2025-2030)
  • Table 688. United Kingdom Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 689. United Kingdom Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 690. United Kingdom Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 691. United Kingdom Famotidine Sales, by End User Tons (2025-2030)
  • Table 692. Netherlands Famotidine Sales, by Type Tons (2025-2030)
  • Table 693. Netherlands Famotidine Sales, by Application Tons (2025-2030)
  • Table 694. Netherlands Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 695. Netherlands Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 696. Netherlands Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 697. Netherlands Famotidine Sales, by End User Tons (2025-2030)
  • Table 698. Rest of Europe Famotidine Sales, by Type Tons (2025-2030)
  • Table 699. Rest of Europe Famotidine Sales, by Application Tons (2025-2030)
  • Table 700. Rest of Europe Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 701. Rest of Europe Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 702. Rest of Europe Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 703. Rest of Europe Famotidine Sales, by End User Tons (2025-2030)
  • Table 704. MEA Famotidine Sales, by Country Tons (2025-2030)
  • Table 705. MEA Famotidine Sales, by Type Tons (2025-2030)
  • Table 706. MEA Famotidine Sales, by Application Tons (2025-2030)
  • Table 707. MEA Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 708. MEA Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 709. MEA Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 710. MEA Famotidine Sales, by End User Tons (2025-2030)
  • Table 711. Middle East Famotidine Sales, by Type Tons (2025-2030)
  • Table 712. Middle East Famotidine Sales, by Application Tons (2025-2030)
  • Table 713. Middle East Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 714. Middle East Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 715. Middle East Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 716. Middle East Famotidine Sales, by End User Tons (2025-2030)
  • Table 717. Africa Famotidine Sales, by Type Tons (2025-2030)
  • Table 718. Africa Famotidine Sales, by Application Tons (2025-2030)
  • Table 719. Africa Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 720. Africa Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 721. Africa Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 722. Africa Famotidine Sales, by End User Tons (2025-2030)
  • Table 723. North America Famotidine Sales, by Country Tons (2025-2030)
  • Table 724. North America Famotidine Sales, by Type Tons (2025-2030)
  • Table 725. North America Famotidine Sales, by Application Tons (2025-2030)
  • Table 726. North America Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 727. North America Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 728. North America Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 729. North America Famotidine Sales, by End User Tons (2025-2030)
  • Table 730. United States Famotidine Sales, by Type Tons (2025-2030)
  • Table 731. United States Famotidine Sales, by Application Tons (2025-2030)
  • Table 732. United States Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 733. United States Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 734. United States Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 735. United States Famotidine Sales, by End User Tons (2025-2030)
  • Table 736. Canada Famotidine Sales, by Type Tons (2025-2030)
  • Table 737. Canada Famotidine Sales, by Application Tons (2025-2030)
  • Table 738. Canada Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 739. Canada Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 740. Canada Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 741. Canada Famotidine Sales, by End User Tons (2025-2030)
  • Table 742. Mexico Famotidine Sales, by Type Tons (2025-2030)
  • Table 743. Mexico Famotidine Sales, by Application Tons (2025-2030)
  • Table 744. Mexico Famotidine Sales, by Route of Administration Tons (2025-2030)
  • Table 745. Mexico Famotidine Sales, by Treatment Tons (2025-2030)
  • Table 746. Mexico Famotidine Sales, by Dosage Tons (2025-2030)
  • Table 747. Mexico Famotidine Sales, by End User Tons (2025-2030)
  • Table 748. Famotidine: by Type(USD/Units)
  • Table 749. Research Programs/Design for This Report
  • Table 750. Key Data Information from Secondary Sources
  • Table 751. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Famotidine: by Type USD Million (2018-2023)
  • Figure 5. Global Famotidine: by Application USD Million (2018-2023)
  • Figure 6. Global Famotidine: by Route of Administration USD Million (2018-2023)
  • Figure 7. Global Famotidine: by Treatment USD Million (2018-2023)
  • Figure 8. Global Famotidine: by Dosage USD Million (2018-2023)
  • Figure 9. Global Famotidine: by End User USD Million (2018-2023)
  • Figure 10. South America Famotidine Share (%), by Country
  • Figure 11. Asia Pacific Famotidine Share (%), by Country
  • Figure 12. Europe Famotidine Share (%), by Country
  • Figure 13. MEA Famotidine Share (%), by Country
  • Figure 14. North America Famotidine Share (%), by Country
  • Figure 15. Global Famotidine: by Type Tons (2018-2023)
  • Figure 16. Global Famotidine: by Application Tons (2018-2023)
  • Figure 17. Global Famotidine: by Route of Administration Tons (2018-2023)
  • Figure 18. Global Famotidine: by Treatment Tons (2018-2023)
  • Figure 19. Global Famotidine: by Dosage Tons (2018-2023)
  • Figure 20. Global Famotidine: by End User Tons (2018-2023)
  • Figure 21. South America Famotidine Share (%), by Country
  • Figure 22. Asia Pacific Famotidine Share (%), by Country
  • Figure 23. Europe Famotidine Share (%), by Country
  • Figure 24. MEA Famotidine Share (%), by Country
  • Figure 25. North America Famotidine Share (%), by Country
  • Figure 26. Global Famotidine: by Type USD/Units (2018-2023)
  • Figure 27. Global Famotidine share by Players 2023 (%)
  • Figure 28. Global Famotidine share by Players (Top 3) 2023(%)
  • Figure 29. Global Famotidine share by Players (Top 5) 2023(%)
  • Figure 30. BCG Matrix for key Companies
  • Figure 31. Uquifa (Spain) Revenue, Net Income and Gross profit
  • Figure 32. Uquifa (Spain) Revenue: by Geography 2023
  • Figure 33. Rakshit Drugs Private Limited (India) Revenue, Net Income and Gross profit
  • Figure 34. Rakshit Drugs Private Limited (India) Revenue: by Geography 2023
  • Figure 35. Chempro Pharma (India) Revenue, Net Income and Gross profit
  • Figure 36. Chempro Pharma (India) Revenue: by Geography 2023
  • Figure 37. Gauri Fine Chemicals (India) Revenue, Net Income and Gross profit
  • Figure 38. Gauri Fine Chemicals (India) Revenue: by Geography 2023
  • Figure 39. Darou Pakhsh Pharma Chem Co. (Iran) Revenue, Net Income and Gross profit
  • Figure 40. Darou Pakhsh Pharma Chem Co. (Iran) Revenue: by Geography 2023
  • Figure 41. Pat Impex (India) Revenue, Net Income and Gross profit
  • Figure 42. Pat Impex (India) Revenue: by Geography 2023
  • Figure 43. Wuhan Jayusion Pharmaceutical Technology Co., Ltd (China) Revenue, Net Income and Gross profit
  • Figure 44. Wuhan Jayusion Pharmaceutical Technology Co., Ltd (China) Revenue: by Geography 2023
  • Figure 45. Phalanx Labs (India) Revenue, Net Income and Gross profit
  • Figure 46. Phalanx Labs (India) Revenue: by Geography 2023
  • Figure 47. Teva Pharmaceuticals (United States) Revenue, Net Income and Gross profit
  • Figure 48. Teva Pharmaceuticals (United States) Revenue: by Geography 2023
  • Figure 49. Aurobindo Pharma (United States) Revenue, Net Income and Gross profit
  • Figure 50. Aurobindo Pharma (United States) Revenue: by Geography 2023
  • Figure 51. Alembic Pharmaceuticals Inc (United States) Revenue, Net Income and Gross profit
  • Figure 52. Alembic Pharmaceuticals Inc (United States) Revenue: by Geography 2023
  • Figure 53. Mylan Laboratories Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 54. Mylan Laboratories Ltd. (United States) Revenue: by Geography 2023
  • Figure 55. Ercros (Spain) Revenue, Net Income and Gross profit
  • Figure 56. Ercros (Spain) Revenue: by Geography 2023
  • Figure 57. Jeil Pharmaceutical (South Korea) Revenue, Net Income and Gross profit
  • Figure 58. Jeil Pharmaceutical (South Korea) Revenue: by Geography 2023
  • Figure 59. Global Famotidine: by Type USD Million (2025-2030)
  • Figure 60. Global Famotidine: by Application USD Million (2025-2030)
  • Figure 61. Global Famotidine: by Route of Administration USD Million (2025-2030)
  • Figure 62. Global Famotidine: by Treatment USD Million (2025-2030)
  • Figure 63. Global Famotidine: by Dosage USD Million (2025-2030)
  • Figure 64. Global Famotidine: by End User USD Million (2025-2030)
  • Figure 65. South America Famotidine Share (%), by Country
  • Figure 66. Asia Pacific Famotidine Share (%), by Country
  • Figure 67. Europe Famotidine Share (%), by Country
  • Figure 68. MEA Famotidine Share (%), by Country
  • Figure 69. North America Famotidine Share (%), by Country
  • Figure 70. Global Famotidine: by Type Tons (2025-2030)
  • Figure 71. Global Famotidine: by Application Tons (2025-2030)
  • Figure 72. Global Famotidine: by Route of Administration Tons (2025-2030)
  • Figure 73. Global Famotidine: by Treatment Tons (2025-2030)
  • Figure 74. Global Famotidine: by Dosage Tons (2025-2030)
  • Figure 75. Global Famotidine: by End User Tons (2025-2030)
  • Figure 76. South America Famotidine Share (%), by Country
  • Figure 77. Asia Pacific Famotidine Share (%), by Country
  • Figure 78. Europe Famotidine Share (%), by Country
  • Figure 79. MEA Famotidine Share (%), by Country
  • Figure 80. North America Famotidine Share (%), by Country
  • Figure 81. Global Famotidine: by Type USD/Units (2025-2030)
List of companies from research coverage that are profiled in the study
  • Uquifa (Spain)
  • Rakshit Drugs Private Limited (India)
  • Chempro Pharma (India)
  • Gauri Fine Chemicals (India)
  • Darou Pakhsh Pharma Chem Co. (Iran)
  • Pat Impex (India)
  • Wuhan Jayusion Pharmaceutical Technology Co., Ltd (China)
  • Phalanx Labs (India)
  • Teva Pharmaceuticals (United States)
  • Aurobindo Pharma (United States)
  • Alembic Pharmaceuticals Inc (United States)
  • Mylan Laboratories Ltd. (United States)
  • Ercros (Spain)
  • Jeil Pharmaceutical (South Korea)
Select User Access Type

Key Highlights of Report


Feb 2024 236 Pages 97 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Famotidine Market Quantitative research analysis
Global Famotidine Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Top performing companies in the Global Famotidine market are Uquifa (Spain), Rakshit Drugs Private Limited (India), Chempro Pharma (India), Gauri Fine Chemicals (India), Darou Pakhsh Pharma Chem Co. (Iran), Pat Impex (India), Wuhan Jayusion Pharmaceutical Technology Co., Ltd (China), Phalanx Labs (India), Teva Pharmaceuticals (United States), Aurobindo Pharma (United States), Alembic Pharmaceuticals Inc (United States), Mylan Laboratories Ltd. (United States), Ercros (Spain) and Jeil Pharmaceutical (South Korea), to name a few.
"Treatment for Esophagitis" is seen as one of major influencing trends for Famotidine Market during projected period 2023-2030.
Solution segment in Global market to hold robust market share owing to "Increasing Use of Famotidine to Treat Acid Indigestion ".

Know More About Global Famotidine Market Report?

Have a Query? Click Here

Other Related Reports

Multivitamin Capsules Comprehensive Study by Application (Energy & Weight Management, General Health, Bone & Joint Health, Gastrointestinal Health, Immunity, Cardiac Health, Diabetes, Anti-Cancer, Ot...
$ 3650
Antibacterial Card Comprehensive Study by Type (Hang Neck Type, Clip-on Type), Application (Hospital Use, Clinic Use, Household, Other), Distribution Channel (Online, Offline), End Use (Adult, Childr...
$ 3500
Sarcoidosis Drug Comprehensive Study by Type (Corticosteroids, Immune Suppressants (methotrexate and azathioprine), Hydroxychloroquine, Tumor Necrosis Factor-alpha (TNF-alpha) Inhibitors), Disease Ty...
$ 3750
Chemical Drugs Comprehensive Study by Application (Cardiovascular Diseases, Diabetes, Central Nervous System Disorders, Respiratory Diseases, Infectious Diseases, Autoimmune Diseases), Route of Admin...
$ 3800
Psychedelic Drugs Comprehensive Study by Application (Major Depressive Disorder, Resistant Depression, Panic Disorder, Post-traumatic Stress Disorder, Opiate Addiction, Others), Drug Type (Lysergic A...
$ 3750
Olanzapine Comprehensive Study by Type (Patent, Generics), Application (Schizophrenia, Bipolar Disorder, Other), Product Type (Tablet, Injection), Sales Channel (Online Pharmacy, Hospital Pharmacy, R...
$ 3350